Aptimmune launches inactivated mucosal influenza A virus vaccine in swine (IAV-S)

IAV-S vaccine utilizes the BARRICADE proprietary vaccine formulation

November 15, 2017

2 Min Read
Aptimmune launches inactivated mucosal influenza A virus vaccine in swine (IAV-S)

Aptimmune Biologics has introduced the industry’s first inactivated mucosal influenza A virus in swine (IAV-S) vaccine administered via nasal spray.

Aptimmune’s IAV-S vaccine utilizes the BARRICADE proprietary vaccine formulation that gives swine producers and veterinarians a completely different approach to conventional inactivated injectable and live virus vaccines for safely preventing and managing respiratory disease.

This inactivated mucosal vaccine is a new class of vaccines that mitigates respiratory disease at the point of entry, the company said, noting that BARRICADE IAV-S combines three core components essential for effective disease protection: first, contemporary influenza type A antigen relevant for current application; second, a powerful and safe immune-stimulating adjuvant, and third, Aptimmune’s proprietary nanoparticles deliver the vaccine payload to immune cells at the mucosal surface.

“BARRICADE IAV-S has shown to target immune cells at the respiratory surface, where the pig is naturally exposed to infection. BARRICADE’s revolutionary approach provides veterinarians and producers the opportunity to produce an IAV-S vaccine which may contain up to five contemporary influenza type A strains, such as H1N1, H1N2 and H3N2,” said Jessica Seate, professional services veterinarian for Aptimmune Biologics.

“This inactivated-virus mucosal vaccine with its needleless, intranasal administration is safe to pigs, people, and is PQA-Plus friendly, making it an effective alternative to conventional IAV-S vaccines," Seate said.

BARRICADE IAV-S is the second intranasally administered mucosal swine vaccine product introduced by Aptimmune this year, Aptimmune chief executive officer Aaron Gilbertie noted. “Our BARRICADE PRRS vaccine continues to perform well on swine farms across the country, under some of the toughest disease conditions, and has validated our collaborative innovation model for developing and manufacturing custom mucosal vaccines. And because our PRRS and IAV-S vaccines utilize the same BARRICADE technology, they can be combined and administered together to prevent these two important diseases when appropriate.”

BARRICADE IAV-S vaccine is available in 250 mL and 500 mL bottles. The company recommends pigs be vaccinated intranasally once at 7-10 days of age and again at weaning (approximately 3-4 weeks of age). Aptimmune’s IAV-S vaccine formulated with BARRICADE technology includes a 21-day withdrawal period, the shortest allowed for custom vaccines.

Aptimmune Biologics, based in Champaign, Ill., specializes in developing and marketing a portfolio of revolutionary mucosal vaccines that provide answers for the most costly viral diseases impacting the swine industry. Aptimmune’s first vaccines are focused on addressing two major viral respiratory pathogens, porcine reproductive and respiratory syndrome virus (PRRSV) and influenza A virus in swine.

Subscribe to Our Newsletters
Feedstuffs is the news source for animal agriculture

You May Also Like